To expand the availability of treatment for patients with viral hepatitis C, the Russian government has initiated the ‘Combatting Hepatitis C’ federal project, which will kick off in 2025 as part of the ‘A Long and Active Life’ national project and will include preferential drug provision. To detect the disease at an early stage and clarify information about the prevalence of hepatitis C in the country, screening for hepatitis C antibodies has been included in preventive and medical examinations of certain groups of the adult population starting this year. In addition, the federal register of patients with chronic viral hepatitis just recently started working officially. What are the current criteria for providing medical care to patients with hepatitis C using compulsory medical insurance? What additional state support measures could improve the availability and quality of antiviral therapy for various groups of the population? How can we evaluate the experience of the regions in organizing preferential drug provision and what new opportunities exist to expand it?